tbuckley/cabot-search huggingface dataset:
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Authors: M Markman, M George, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis
Journal: Journal of Clinical Oncology (1990)

To define both the toxicity and efficacy of intraperitoneal mitoxantrone in the treatment of refractory ovarian carcinoma, 31 patients were entered onto a phase II trial of this agent delivered in a 2 L treatment volume on a monthly basis. Due to excessive local pain at the initial dose level (30 mg/m2), the amount of drug delivered with each treatment course was reduced to 20 mg/m2. Despite this reduction, 74% of patients required narcotic analgesia during treatment. In addition, there were four episodes of bowel obstruction (one requiring surgical intervention) during therapy, and two patients developed bowel obstruction and intraabdominal abscesses following the completion of treatment. Six of 18 evaluable patients (33%) whose largest tumor diameter was less than or equal to 1 cm at protocol initiation experienced surgically documented responses, compared with one of 11 patients (9%) whose largest tumor was greater than 1 cm in diameter. If the two patients exhibiting what we called a mixed response to treatment are included, seven of 21 patients previously treated with intraperitoneal cisplatin responded to this treatment program, including four patients who had failed to respond to intraperitoneal cisplatin. No responding patient has demonstrated clinical evidence of relapse with a median follow-up of 7 months (range, 3+ to 13+ months) from response laparotomy. Intraperitoneal mitoxantrone is an active treatment program in patients with small-volume refractory ovarian carcinoma, but local toxicity can be severe. Due to the toxicity encountered with this specific program, its use cannot be recommended for standard clinical practice. However, in view of the activity observed in refractory ovarian carcinoma, including responses in patients who had previously failed intraperitoneal cisplatin, it is important to continue to explore alternative therapeutic regimens using intraperitoneal mitoxantrone to reduce local toxicity while maintaining or improving efficacy.
BMS-354825 induced complete hematologic remission in chronic phase CML patients without affecting T-cell cytokine production
Authors: H. Gao, M. Talpaz, B. N. Lee, N. Donato, J. E. Cortes, H. M. Kantarjian, J. M. Reuben
Journal: Journal of Clinical Oncology (2005)

6619 Background: Both in vitro and murine studies showed that the BMS-354825 is a potent Src and Abl kinases inhibitor that binds to the active and inactive conformation of Bcr-Abl. Since Src-family kinases are important modulators of T cell activation, the effects of BMS-354825 on T cell cytokine synthesis was evaluated in chronic phase CML patients who had failed therapy with imatinib and were receiving BMS-354825. Methods: Blood was obtained from 14 chronic phase CML patients on days 1 (baseline), 5, and 26 of course 1 of treatment with BMS-354825 at total daily doses ranging from 15 mg to 180 mg (given as a single or divided daily dose). White blood cell (WBC) count and leukocyte differential, and %CD3, %CD4, and %CD8 T cells were determined. An aliquot of the whole blood was activated with Staphylococcus enterotoxin B (SEB) to evaluate intracellular cytokine synthesis (ICS) of Th1 (IL-2, IFN-γ, TNF-α) and Th2 (IL-10) cytokines by CD4+ and CD8+T cells by FACS. Statistical differences in WBC, %CD3+, %CD4+, and %CD8+ T cells, and ICS by CD4+ T and CD8+ T cells on days 1, 5, and 26 were determined by ANOVA and LSD methods. Results: Complete hematologic remission (CHR) was achieved in 13 out of the 14 patients without any change in distribution of T-cell subsets. The mean percentages of SEB-activated CD4+ and CD8+ T cells synthesizing IL-2, IFN-γ, TNF-α, and IL-10 on days 5 and 26 were similar to those of baseline (6.0%, 5.6%, 9.7%, and 1.4% for CD4+ T cells and 3.1%, 10.3%, 7.5% and 1.1% for CD8+ T cells, respectively). Regardless of the dose and dosing, there were no significant changes in ICS by SEB-activated T cells during BMS-354825 treatment. Conclusions: Treatment of chronic phase CML patients with BMS-354825 at doses ranging from 15 mg to 180 mg effectively induced CHR in chronic phase CML patients without affecting the ability of SEB-activated CD4+ T and CD8+ T cells to synthesize Th1 and Th2 cytokines in vitro. No significant financial relationships to disclose.
Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer?
Authors: M Bhattacharyya, R Sarin
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.2.802 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9469375 Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer? M BhattacharyyaxM BhattacharyyaSearch for articles by this author , R SarinxR SarinSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.2.802 PDF "Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer?." Journal of Clinical Oncology, 16(2), pp. 802–803© 1998 by American Society of Clinical Oncology
Differences in Spleen Suppressor Cell Content in Rats With Progressing and Regressing Tumors&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Michael A. Hollingsworth, Donald L. Evans
Journal: JNCI Journal of the National Cancer Institute (1982)

Young New Zealand Black rats (<35 wk old) developed progressively growing tumors when given injections of cells from a syngeneic 3-methylcholanthrene (MCA)-induced fibrosarcoma. Spontaneous tumor regression occurred in animals more than 10 months of age. Compared to the responses of spleen cells from age-matched controls, spleen cells from rats in which tumor progression was present (progressor rats) showed decreased proliferative responses to concanavalin (Con A), phytohemagglutinin (PHA), and syngeneic MCA tumor cells. Spleen cells from rats in which the tumors had regressed (regressor rats), however, produced significant increases in proliferative responses when compared with the responses of spleen cells from age-matched controls and from progressor rats. Cell-mixing experiments implicated the presence of two spleen suppressor cell populations in progressor rats, one of which was not present in regressor rats. The unique suppressor cell found in progressor rats appeared to be specific for tumor cell-induced proliferative responses. Spleen cells from both progressor and regressor rats produced similar suppressive effects in the PHA and Con A responses of normal cells.
Concurrent radiation therapy and weekly docetaxel in elderly patients with oropharyngeal carcinoma
Authors: A. Rodica Maricela, L. Oprea, L. Minea, X. Bacinschi, V. Primejdie, I. Florea
Journal: Journal of Clinical Oncology (2008)

6049 Background: Our goal was to evaluate the compliance and efficacy of concurrent weekly docetaxel and radiation therapy as definitive treatment for elderly patients with oropharyngeal carcinoma. Methods: 20 patients, over 65 years of age, with primary oropharyngeal cancer, who were treated with concurrent docetaxel and radiation therapy, were reported between January 2005 and December 2006. The distribution depending on stage was: stage II - 4 patients, stage III - 6 patients, stage IV - 10 patients (IV A - 7 patients and IV B - 3 patients). The total dose of radiotherapy was 70 Gy. Chemotherapy was delivered weekly and consisted in Docetaxel 10 mg/sqm. 4 more cycles of chemotherapy (Docetaxel and Cisplatin) were administrated after concurrent radiochemotherapy. Results: Only 2 patients interrupted the radiochemotherapy due to related toxicities, especially acute grade III - IV mucositis. Grade III - IV hematological toxicities were observed in 5 patients, and grade III - IV mucositis in 4 patients. At the time of analysis 18 patients are alive and 11 of them are disease free. Conclusions: Concurrent weekly docetaxel and radiation therapy did not affect patients' compliance to treatment; acute toxicities were in acceptable limits. Concurrent radio - chemotherapy was well tolerated and results and acute toxicities were comparable with younger patients. Elderly cancer patients should be offered optimal treatment depending on their functional status not on chronological age. No significant financial relationships to disclose.
(Auto)antibodies in Human Breast Cancer Sera Against Antigens Associated With Breast Cancer Cells, Detected by Immunoblotting&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Z Ronai, D Sulitzeanu
Journal: JNCI Journal of the National Cancer Institute (1986)

Sera of patients with breast cancer (as well as control normal sera and sera of patients with ovarian cancer or melanoma) were screened for the presence of antibodies against antigens expressed by the MDA breast cancer cell line. The techniques employed were radioimmunoassay with radioiodinated protein A and immunodotting with peroxidase-conjugated anti-human immunoglobulin antibodies. Sera reacting strongly by immunodotting were subsequently tested against antigens of the MDA and T47D cell lines in immunoblotting experiments. Both the breast cancer and the control sera yielded highly complex band patterns, which varied from serum to serum. The cancer sera differed from the normal sera, however, as they produced in most cases one or several bands that were distinctly stronger than the others. One of the strong bands, in fact a doublet of approximately 50 kilodaltons (kd), was produced preferentially (although not exclusively) when breast cancer sera were reacted with T47D cell membrane antigens. Absorption of selected sera with normal tissue or MDA antigens abolished or greatly reduced the intensity of some of the bands. It is concluded that, with the possible exception of the 50-kd band, most (probably all) of the bands seen in immunoblots resulted from the binding of autoantibodies to normal antigens expressed by the breast cancer cell lines. The main difference between cancer and normal sera would seem to be an increased content of autoantibodies in cancer, the specificity of these autoantibodies varying, however, from serum to serum.
Dynein Regulator NDEL1 Controls Polarized Cargo Transport at the Axon Initial Segment
Authors: Marijn Kuijpers, Dieudonnée van de Willige, Amélie Freal, Anaël Chazeau, Mariella A. Franker, Jasper Hofenk, Ricardo J. Cordeiro Rodrigues, Lukas C. Kapitein, Anna Akhmanova, Dick Jaarsma, Casper C. Hoogenraad
Journal: Neuron (2016)
Effect of Cysteinyl Leukotriene Receptor Antagonists on Leukotirene D4-Induced Chemotaxis of Human Eosinophilc Cell Line, Eol-1 Cells
Authors: Hideaki Shirasaki, Etsuko Kanaizumi, Manabu Fujita, Tomohiko Sekioka, Tetsuo Himi
Journal: Journal of Allergy and Clinical Immunology (2016)
Cutaneous Malignant Melanoma and Fluorescent Lighting&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: D R English, I L Rouse, Z Xu, J D Watt, C D Holman, P J Heenan, B K Armstrong
Journal: JNCI Journal of the National Cancer Institute (1985)

A population-based case-control study of cutaneous malignant melanoma occurring during 1980-81 was conducted in Perth, Western Australia. Three hundred and thirty-seven cases and 349 matched controls were reinterviewed in 1983 with regard to their fluorescent light exposure. The incidence rate of all melanomas was not associated with rate of exposure or cumulative exposure to all fluorescent lights or just those without diffusers. Separate analyses by histogenetic type and, where possible, body site of melanoma showed, in most instances, no consistent association between incidence rate of melanoma and exposure to fluorescent lights without diffusers. Incidence of melanomas of unclassifiable histogenetic type, however, increased with increasing duration of exposure (P-value for trend .02). This association was weaker and the P-value higher (.11) when exposure was considered only in residential rooms and offices, where light fittings are closest to the subject. Adjustment for the effects of total and intermittent sun exposure on melanoma rates did not alter the above trends appreciably.
Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status
Authors: Ashkan Emadi, Mariola Sadowska, Brandon Carter-Cooper, Omasiri Wonodi, Nidal Muvarak, Feyruz Rassool, Anil Jaiswal, Maria R. Baer, Rena G. Lapidus, Edward A. Sausville
Journal: Blood (2013)
Cost of combined modality interventions for stage III non-small-cell lung cancer.
Authors: W K Evans, B P Will, J M Berthelot, C C Earle
Journal: Journal of Clinical Oncology (1997)

To evaluate the cost-effectiveness (CE) of new combined modality strategies in patients with stage III non-small-cell lung cancer (NSCLC).Recent studies suggest that combined modality therapy confers a survival advantage for patients with stage III NSCLC. Using the Statistics Canada (Ottawa, Canada) lung cancer costing model, we have evaluated the CE of these interventions using 1993 Canadian health care costs and the perspective of the government as payer in a universal health care system.We estimate that the cost to treat a stage IIIa NSCLC patient with preoperative and postoperative chemotherapy would increase by $15,886, and a similar combined modality approach with the addition of postoperative radiotherapy would increase the cost by $22,963. Chemoradiotherapy for stage IIIb NSCLC would produce a smaller incremental cost of approximately $8,912 per case. However, these approaches are remarkably cost-effective, with cost per life-year gained (LYG) ranging from $3,348 to $14,958. Administering all chemotherapy in the outpatient department would improve CE. For sensitivity analysis, we reduced the survival gain that resulted from the three interventions by 25% and 50%, and increased the hospital per diem rates by 10%, 20%, and 30%.Even with the most adverse assumptions, the CE estimates were all considered acceptable for new health care technologies in Canada. Overall, it appears that neoadjuvant therapy for stage IIIa NSCLC and combined modality therapy for stage IIIb NSCLC are cost-effective. Economic considerations should not be a barrier to their adoption.
Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM
Authors: C. I. Chen, T. Kouroukis, D. White, M. Voralia, E. Stadtmauer, J. Wright, J. Powers, E. Eisenhauer
Journal: Journal of Clinical Oncology (2006)

7543 Background: WM is a B cell lymphoma characterized by a serum monoclonal IgM and marrow infiltration by lymphoplasmacytoid cells. Bortezomib is a proteasome inhibitor active in myeloma and other hematologic malignancies. In this 2-stage study, 27 WM pts received single agent bortezomib with RR as primary endpoint. Methods: Eligibility: symptomatic WM (Hb &lt;110 g/L; lymphadenopathy; organomegaly; or hyperviscosity); ≤2 prior chemo regimens (± rituximab). Bortezomib 1.3 mg/m 2 IV given d1, 4, 8, 11 on a 21d cycle until PD or 2 cycles beyond CR/SD. Nodal disease was included in response criteria (2nd International WM Workshop). Results: Median age 65 (46–87), M:F 14:13, no prior therapy 11 (44%). At entry, median IgM 38 g/L (11.2–83.3); median Hb 108 g/L (63–142); 18 (66%) with nodal disease on CT. At a median of 6 cycles (2–35), 11/27 (41%) patients had ≥50% decrease in IgM alone plus 10 (37%) minor responses (25–49% decrease). Using IgM + nodal criteria: 1 CR, 5 PR (≥50% decrease in IgM and bidimensional disease), 20 SD, 1 PD = overall RR 22% (95% CI 8.6–42.2%). IgM responses were prompt (median 2 cycles; range 1–8) with nodal responses lagging (median 4 cycles). Hb increased by ≥10g/L in 18 pts (66%). Bortezomib was well-tolerated with most non-hematologic toxicities Gr 1–2: fatigue (74%), nausea (63%), myalgias (51%), non-neutropenic infections (48%), diarrhea (44%), constipation (44%). 18 pts (66%) developed neuropathy (sensory): typical onset 2–4 cycles; Gr 3 in 5 pts; 15/18 (83%) improving ≥1 grade (11 complete) in 2–13 mo. Gr 3 myalgias in 2 pts resolved in &lt;1 mo. Gr 3–4 thrombocytopenia (30%) and neutropenia (18%) led to 12 missed doses, 1 dose reduction. Conclusions: Bortezomib is active in WM with 78% pts with ≥25% fall in IgM, 41% with IgM response criteria of ≥50% decrease, 22% with composite nodal/IgM responses. Despite prompt IgM and hematologic improvement, decrease in nodal disease is slow, reflected in overall responses lower than IgM alone. Although bortezomib is generally well-tolerated, neuropathy is common but reversible. Bortezomib combinations with conventional cytotoxic or targeted agents warrant further study in WM. This is a NCIC CTG study with a grant from NCIC and funds from Canadian Cancer Society. [Table: see text]
Prognostic value of ABCF2 in ovarian clear cell adenocarcinoma
Authors: H. Tsuda, Y. M. Ito, K. Ito, S. Nishimura, N. Yaegashi, M. J. Birrer, Y. Ohashi, Y. Hashiguchi, R. S. Berkowitz, S. C. Mok
Journal: Journal of Clinical Oncology (2005)

5037 Background: Ovarian clear cell adenocarcinoma (CC) generally shows little response to combination chemotherapy and the overall prognosis is poor. However, the molecular pathobiology of CC remains largely unknown, because this is a rare type of ovarian cancer. We previously reported that ABCF2, which is a new member of the ATP-binding cassette transporter superfamily, gene might be a new biomarker for CC using cDNA microarray analysis (Proc ASCO 2003 22:448a). In this study, we raised a polyclonal antibody directed against ABCF2 and evaluated the relationship between ABCF2 expression and the response to chemotherapy or overall survival (OS) in CC patients. Methods: Formalin-fixed surgical samples were obtained from 61 CC patients and ABCF2 expression was investigated by immunohistochemostry. The percentage of positive cytoplasmic staining for ABCF2 was calculated by examining at least 1000 tumor cells. In 28 patients, quantitative RT-PCR was performed to evaluate the relationship between level of ABCF2 protein expression and relative mRNA expression. Results: The clinical stage was I in 28 patients, II in 10 patients, III in 22 patients, and IV in 1 patients. Fifty six patients received platinum-based chemotherapy after primary debulking surgery and the response to chemotherapy was evaluable in 12 of them. Forty-three out of 61 (70.5%) patients showed ABCF2 expression in the cytoplasm of tumor cells and the relative mRNA expression was significantly correlated with level of ABCF2 protein expression (r=0.504, p=0.006). There was no significant difference of ABCF2 protein expression between stages I+II and stages III+IV. A clinical response to chemotherapy was obtained in 5 cases. Non responders had significantly higher level of ABCF2 protein expression than responders (58.6% vs. 25%, p=0.0007). For the entire cohort, the OS was 75.4% (median follow-up of 36 months). The OS of 67.4% (median follow-up of 36 months) for patients with ABCF2 expression in their tumors was significantly worse than the OS of 94.4% (median follow-up of 37 months) for patients without tumor ABCF2 expression (p=0.03). Conclusions: The present results indicate that ABCF2 expression may predict the response to chemotherapy and survival of CC patients. No significant financial relationships to disclose.
A single-center, retrospective chart review evaluating outpatient code status documentation in the EPIC electronic medical record for patients with advanced solid tumor cancer.
Authors: John M. Horton, Michael Hwang, Joseph D. Ma, Eric Roeland
Journal: Journal of Clinical Oncology (2013)

242 Background: A desired code status is a critical element of advance care planning ideally outlined in an advance directive. Preferably, advance care planning occurs in the non-emergent, outpatient setting. In the absence of a documented code status, full resuscitation is the default, which is not desired by all patients. Currently, unlike the inpatient setting, there is no single, convenient location for code status documentation in the outpatient EPIC electronic medical record (EMR). In order to propose a system-wide solution, a retrospective chart review was completed to assess the scope of the problem. Methods: 160 charts were randomly selected of advanced solid tumor cancer patients (stage III-IV) who received care by a medical oncologist at the UCSD Moores Cancer Center from 2008-2011. The primary objective was to determine the incidence of code status documentation. Secondary objectives included determining the clinical role of the documenter and the code status documentation location within the EMR. Results: 57 advanced cancer patients (36%) had code status documented in 9 different locations in the EMR. Of the 57 patients, only 4 (7%) had a code status documented in the outpatient setting. When documented, code status was located in the progress note (5%), demographics tab (26%), problem list (2%), and scanned media section (14%). Out of the 160 charts, the outpatient oncologist documented the code status in 1 chart. Inpatient EMR locations of the code status included the discharge summary (33%), history and physical (11%), and progress note (9%). Conclusions: In the absence of a standard EPIC outpatient code status documentation procedure, code status was infrequently and inconsistently documented. Consequently, a readily available and accurate code status is not present for emergencies in the outpatient setting. With this information, we will focus future efforts on a clearly defined, standard, and convenient location for outpatient code status documentation in the EPIC EMR.